Formula 1 PGT Inhibitors for Specific Prostaglandin Transport Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prostaglandin transporter (PGT) inhibitors are non-specific, leading to off-target effects, and there is a need for targeted and efficacious PGT inhibitors to manage conditions associated with prostaglandin levels, COX1 and COX2 activity, and to increase systemic levels of prostaglandin E2 and endogenous prostacyclin.
Innovation Solution
Development of a compound of Formula (1) and its pharmaceutically acceptable salts, which specifically inhibit PGT, thereby modulating prostaglandin signaling pathways and increasing PGE2 levels to treat conditions such as dysregulated hyperinflammation and pulmonary arterial hypertension.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific PGT inhibitors (such as bromcresol green, bromosulfophthalein, indomethacin, ibuprofen) are used, then PGT inhibition is achieved, but off-target effects occur due to lack of specificity
Solution Approach 1:
The patent modifies the chemical structure of PGT inhibitors by changing molecular parameters (introducing specific functional groups, modifying side chains, adjusting molecular weight and lipophilicity) to achieve high specificity for PGT while maintaining inhibition efficacy and reducing off-target effects
Solution Approach 2:
The invention creates local quality differentiation by designing inhibitors with specific molecular features that selectively interact with PGT binding sites, while avoiding interactions with other transporters and receptors, thus achieving selective inhibition without off-target effects
2Quantity of substance
If PGT inhibition is used to increase systemic PGE2 levels, then prostaglandin signaling is enhanced, but uncontrolled inflammation and hyperinflammation may occur
Solution Approach 1:
The patent incorporates feedback mechanisms through selective PGT inhibition that allows controlled increase of PGE2 levels while monitoring and preventing excessive inflammation, using the body's own prostaglandin regulation systems to maintain balance
Solution Approach 2:
The invention applies partial action by using selective PGT inhibitors that provide just enough inhibition to achieve therapeutic PGE2 levels without excessive accumulation that would cause hyperinflammation, optimizing the dose-response relationship
3Reliability
If PGT inhibition is used to treat pulmonary arterial hypertension, then endogenous prostacyclin levels increase, but treatment complexity and monitoring requirements increase
Solution Approach 1:
The patent enables self-service treatment by using oral PGT inhibitors that allow patients to self-regulate prostacyclin levels through dietary and lifestyle modifications, eliminating the need for complex intravenous prostacyclin analog administration and monitoring equipment
Solution Approach 2:
The invention replaces expensive, complex continuous intravenous prostacyclin analog delivery systems with affordable, simple oral PGT inhibitor medications that can be taken as needed, reducing treatment complexity and cost
Data Source
AI summary
The disclosure provides compounds of Formula 1, and the pharmaceutically acceptable salts thereof. The variables in Formula 1, e.g. X1-X5, A1, A2, and R1-R4 are described herein. Such compounds are useful as prostaglandin transport (PGT) inhibitors. The disclosure further includes pharmaceutical compositions comprising a compound of Formula 1 or salt thereof and methods of using compounds of Formula 1 and salts thereof to treat diseases and disorders mediated, at least in part, by prostaglandin levels or cyclooxygenase activity. Such diseases and disorders include painful and inflammatory conditions.